CD19 and myeloid neoplasm: Another study of CD19 CAR T within 86 patients reported a pretty higher incidence of second cancers was 15% (n=13), among which non-myeloid neoplasms accounted for 69% and non-melanoma skin cancer accounted for 46% (20).